Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Fondazione G.B. Bietti, IRCCS |
---|---|
Information provided by: | Fondazione G.B. Bietti, IRCCS |
ClinicalTrials.gov Identifier: | NCT00574093 |
This study is designed to evaluate the effect of Visudyne® combination therapy (Visudyne® [verteporfin for injection] and Lucentis™) on visual acuity outcomes. Study results will be submitted for publication to provide data that may help physicians refine the clinical management of patients with CNV secondary to age-related macular degeneration (AMD).
Condition | Intervention | Phase |
---|---|---|
Neovascular Age Related Macular Degeneration |
Drug: Ranibizumab; Verteporfin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | 12 Months Case Series Open Study to Assess the Safety and Efficacy of Intravitreal Injection of Lucentis (Ranibizumab 0.5 mg)Used in Combination With Visudyne (Verteporfin PDT) in Naive Subjects With Subfoveal CNV Secondary to AMD |
Estimated Enrollment: | 15 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | June 2009 |
Estimated Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
A: This will be a single arm study. Patients will be administered Lucentis™ on Day 1,at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3. |
Drug: Ranibizumab; Verteporfin
Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
|
This will be a single arm study. Patients will be administered Lucentis™ on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
Consenting patients will participate in the Screening Period to evaluate study eligibility. Patient eligibility assessments will include BCVA, contrast sensibility, speed reading and VFQ-25, a standard ophthalmic examination, OCT, color fundus photography, Fluorescein Angiography (FA), Green Indocyanine Angiography, Microperimetry and multifocal ERG. BCVA and mean central retinal thickness measured by OCT will be repeated at every follow up visit.
Fluorescein Angiography (FA), Green Indocyanine Angiography, contrast sensibility and speed reading mean retinal sensitivity measured by microperimetry will repeated at month 3, 6, 9 and 12 month.
Color fundus photography at month 1, 3, 6, 9 and 12 month. Multifocal ERG will repeated at month 3 and 12 month.
VFQ-25 will repeated at month 3 and 12. The patient will receive ranibizumab monthly unless the BCVA got worse than 5 letters from the baseline BCVA and
Ages Eligible for Study: | 50 Years to 95 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Monica Varano, MD | +390685356727 | m.varano@mclink.it |
Contact: Adele Chiaravalloti, MD | +390685356727 | a.chiaravalloti@libero.it |
Italy | |
Fondazione G.B.Bietti-IRCCS | Recruiting |
Rome, Italy, 00198 | |
Contact: Annamaria Rocchi +390685356727 annamaria.rocchi@fondazionebietti.it | |
Principal Investigator: Monica Varano, MD | |
Sub-Investigator: Adele Chiaravalloti, MD | |
Sub-Investigator: Mariacristina Parravano, MD | |
Sub-Investigator: Barbara Boccassini, MD | |
Sub-Investigator: Domenico Schiano, MD | |
Sub-Investigator: Massimiliano Tedeschi, MD |
Principal Investigator: | Monica Varano, MD | Fondazione G.B. Bietti, IRCCS |
Responsible Party: | Fondazione G.B. Bietti, IRCCS ( Monica Varano ) |
Study ID Numbers: | CBPD952AIT03 |
Study First Received: | December 13, 2007 |
Last Updated: | January 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00574093 History of Changes |
Health Authority: | Italy: Ethics Committee |
combination therapy Lucentis Visudyne |
Photosensitizing Agents Radiation-Sensitizing Agents Eye Diseases Verteporfin |
Neoplasm Metastasis Retinal Degeneration Macular Degeneration Retinal Diseases |
Photosensitizing Agents Radiation-Sensitizing Agents Therapeutic Uses Eye Diseases Physiological Effects of Drugs Verteporfin |
Retinal Degeneration Macular Degeneration Dermatologic Agents Pharmacologic Actions Retinal Diseases |